{"url_path":"/sec/inbx/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000033-index.html","accession_number":"0002007919-26-000033","cik":"0002007919","ticker":"INBX","issuer_name":"Inhibrx Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000033-index.html","primary_entity_key":"0002007919","primary_entity_name":"Inhibrx Biosciences, Inc."},"word_count":188,"has_tables":true,"body_markdown":"Item 7.01. Regulation FD Disclosure.\n\nOn June 15, 2026, Inhibrx Biosciences, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted for filing its Biologics License Application (the “BLA”) seeking approval of ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}